Valneva SE (VALN) Net Cash Flow (2021 - 2026)
Valneva SE (VALN) posted quarterly Net Cash Flow of -$5.4 million for Q1 2026, up 66.9% year-on-year from -$3.2 million in Q1 2025, and up 86.95% on a QoQ basis from -$41.2 million in Q4 2025.
Valneva SE (VALN) Net Cash Flow (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Net Cash Flow for 6 consecutive years, with -$5.4 million the latest figure, recorded in Q1 2026.
- Quarterly Net Cash Flow rose 66.9% year-over-year to -$5.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$52.0 million (down 83.77% YoY) and the FY2025 annual result came in at -$62.8 million, down 236.76% from the prior year.
- Net Cash Flow rose to -$5.4 million in Q1 2026 per VALN's latest filing, from -$41.2 million in the prior quarter.
- Over the last five years, Net Cash Flow for VALN reached as high as $91.9 billion in Q3 2023 and fell as low as -$92.0 billion in Q2 2023.
- A 5-year average of -$16.0 million and a median of -$16.2 million in 2025 frame the typical range for Net Cash Flow.
- The largest YoY upside for Net Cash Flow was 102503.4% in 2023 against a maximum downside of 324623.36% in 2023.
- Year by year, Net Cash Flow stood at $34.1 million in 2022, then plunged by 253.97% to -$52.6 million in 2023, then jumped by 117.46% to $9.2 million in 2024, then sank by 548.86% to -$41.2 million in 2025, then jumped by 86.95% to -$5.4 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$5.4 million, -$41.2 million, and -$18.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -5.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.38 Mn |
| Mar 31, 2026 | -5.38 Mn |
| Dec 31, 2025 | -41.20 Mn |
| Dec 31, 2025 | -41.20 Mn |
| Sep 30, 2025 | -18.56 Mn |
| Sep 30, 2025 | -18.56 Mn |
| Jun 30, 2025 | 13.16 Mn |
| Jun 30, 2025 | 13.16 Mn |
| Mar 31, 2025 | -16.25 Mn |
| Mar 31, 2025 | -16.25 Mn |
| Dec 31, 2024 | 9.18 Mn |
| Dec 31, 2024 | 9.18 Mn |
| Sep 30, 2024 | 30.10 Mn |
| Sep 30, 2024 | 30.10 Mn |
| Jun 30, 2024 | -51.31 Mn |
| Jun 30, 2024 | -51.31 Mn |
| Mar 31, 2024 | 57.98 Mn |
| Mar 31, 2024 | 57.98 Mn |
| Dec 31, 2023 | -52.57 Mn |
| Dec 31, 2023 | -52.57 Mn |